These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1606592)

  • 1. Formulation study of leuprorelin acetate to improve clinical performance.
    Toguchi H
    Clin Ther; 1992; 14 Suppl A():121-30. PubMed ID: 1606592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical manipulation of leuprorelin acetate to improve clinical performance.
    Toguchi H
    J Int Med Res; 1990; 18 Suppl 1():35-41. PubMed ID: 2138986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats.
    Okada H; Heya T; Ogawa Y; Shimamoto T
    J Pharmacol Exp Ther; 1988 Feb; 244(2):744-50. PubMed ID: 3126294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study.
    Gerhard I; Schindler AE; Bühler K; Winkler U; Meinen K; Mancarella D; Hoffmann G; Schüssler B; Kimmig R; Kranzfelder D
    Clin Ther; 1992; 14 Suppl A():3-16. PubMed ID: 1535021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leuprorelin acetate in prostate cancer: a European update.
    Persad R
    Int J Clin Pract; 2002 Jun; 56(5):389-96. PubMed ID: 12137449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
    Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
    Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leuprorelin acetate granulomas: case reports and review of the literature.
    Yasukawa K; Sawamura D; Sugawara H; Kato N
    Br J Dermatol; 2005 May; 152(5):1045-7. PubMed ID: 15888168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer.
    Berges R; Bello U
    Curr Med Res Opin; 2006 Apr; 22(4):649-55. PubMed ID: 16684425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of depot leuprorelin.
    Periti P; Mazzei T; Mini E
    Clin Pharmacokinet; 2002; 41(7):485-504. PubMed ID: 12083977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
    Cox MC; Scripture CD; Figg WD
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Once-a-month injectable microcapsules of leuprorelin acetate].
    Toguchi H; Ogawa Y; Okada H; Yamamoto M
    Yakugaku Zasshi; 1991 Aug; 111(8):397-409. PubMed ID: 1795229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers.
    Okada H; Doken Y; Ogawa Y; Toguchi H
    Pharm Res; 1994 Aug; 11(8):1143-7. PubMed ID: 7971715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of metastatic prostatic cancer with monthly injections of leuprolide acetate depot].
    Jiménez Cruz JF; Vera Donoso CD; Iborra I; Solsona E; Forner E; Villavicencio H; Díaz C; González C; Rioja L; Pertusa C
    Actas Urol Esp; 1994 Feb; 18(2):90-3. PubMed ID: 7976707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enatone-Gyn monthly depot): a multicenter study].
    Schindler AE; Bühler K; Gerhard I; Wiedemann R; Kimmig R; Schüssler B; Kranzfelder D; Mall-Häfeli M; Meinen K; Mancarella D
    Zentralbl Gynakol; 1994; 116(12):679-86. PubMed ID: 7846980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness and tolerance of three month sustained release leuprorelin in the treatment of metastatic prostatic cancer (comparative, randomized, multicentric study].
    Zerbib M; Lucas C; Leblanc V
    Prog Urol; 1997 Apr; 7(2):246-53. PubMed ID: 9264767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.
    Plosker GL; Brogden RN
    Drugs; 1994 Dec; 48(6):930-67. PubMed ID: 7533699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease of genital organ weights and plasma testosterone levels in rats following oral administration of leuprolide microemulsion.
    Zheng JY; Fulu MY
    Int J Pharm; 2006 Jan; 307(2):209-15. PubMed ID: 16300912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe.
    Tunn UW; Wiedey K
    Prostate Cancer Prostatic Dis; 2009; 12(1):83-7. PubMed ID: 19030021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.